Claims for Patent: 11,072,586

Summary for Patent: 11,072,586

Title:	Solid state forms of eltrombopag choline
Abstract:	Solid state forms of Eltrombopag choline, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
Inventor(s):	Hariprasad Sharma Vijay, Shafakat Ali Nasir Ali, Vijay Joshi Ashutosh, Luthra Parven Kumar, Muthusamy Anantha Rajmohan, Singh Amit, Bate Rajesh Sadanand, Maurya Sadanand Hardeo
Assignee:	ASSIA CHEMICAL INDUSTRIES LTD.
Application Number:	US16753363
Patent Claims:	1. A solid state form of Eltrombopag choline selected from: i. an XRPD pattern having peaks at 11.3, 14.7, 15.4, 16.0 and 24.1 degrees-2-theta±0.2 degrees-2-theta;', {'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'ii. an XRPD pattern as depicted in ; and combinations of any i-ii, or'}], 'A. crystalline form A, which is characterized by data selected from one or more of the following i. an XRPD pattern having peaks at 7.0, 10.2, 13.9, 14.9, 18.3, 21.6 and 26.0 degrees 2-theta±0.2 degrees 2-theta;', {'figref': {'@idref': 'DRAWINGS', 'FIG. 2'}, 'ii. an XRPD pattern as depicted in ; and combinations of any i-ii, or'}], 'B. crystalline form B, which is characterized by data selected from one or more of the following i. an XRPD pattern having peaks at 10.9, 14.2, 15.5, 21.9 and 26.9 degrees 2-theta±0.2 degrees 2-theta;', {'figref': {'@idref': 'DRAWINGS', 'FIG. 5'}, 'ii. an XRPD pattern as depicted in ; and combinations of any i-ii.'}], 'C. crystalline form C, which is characterized by data selected from one or more of the following2. The crystalline Form A of eltrombopag choline according to claim 1 , which is characterized by data selected from one or more of the following:i. an XRPD pattern having peaks at 11.3, 14.7, 15.4, 16.0 and 24.1 degrees-2-theta±0.2 degrees-2-theta;{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'ii. an XRPD pattern as depicted in .'}3. The crystalline Form A of eltrombopag choline according to claim 1 , which is characterized by an XRPD pattern having peaks at 11.3 claim 1 , 14.7 claim 1 , 15.4 claim 1 , 16.0 and 24.1 degrees 2-theta±0.2 degrees 2-theta claim 1 , and also having one claim 1 , two claim 1 , three claim 1 , four claim 1 , five claim 1 , six or seven additional peaks selected from 12.0 claim 1 , 12.7 claim 1 , 14.1 claim 1 , 20.3 claim 1 , 20.9 claim 1 , 24.8 and 27.0 degrees 2-theta±0.2 degrees 2-theta.4. The crystalline Form B of eltrombopag choline according to claim 1 , which is characterized by data selected from one or more of the following:i. an XRPD pattern having peaks at 7.0, 10.2, 13.9, 14.9, 18.3, 21.6 and 26.0 degrees 2-theta±0.2 degrees 2-theta;{'figref': {'@idref': 'DRAWINGS', 'FIG. 2'}, 'ii. an XRPD pattern as depicted in .'}5. The crystalline Form B of eltrombopag choline according to claim 1 , which is characterized an XRPD pattern having peaks at 7.0 claim 1 , 10.2 claim 1 , 13.9 claim 1 , 14.9 claim 1 , 18.3 claim 1 , 21.6 and 26.0 degrees 2-theta±0.2 degrees 2-theta claim 1 , and also having one claim 1 , two claim 1 , three claim 1 , or four additional peaks selected from 7.4 claim 1 , 16.7 claim 1 , 19.9 and 23.9 degrees 2-theta±0.2 degrees 2-theta.6. The crystalline Form C of eltrombopag choline according to claim 1 , which is characterized by data selected from one or more of the following:i. an XRPD pattern having peaks at 10.9, 14.2, 15.5, 21.9 and 26.9 degrees 2-theta±0.2 degrees 2-theta;{'figref': {'@idref': 'DRAWINGS', 'FIG. 5'}, 'ii. an XRPD pattern as depicted in .'}7. The crystalline Form C of eltrombopag choline according to claim 1 , which is characterized by an XRPD pattern having peaks at 10.9 claim 1 , 14.2 claim 1 , 15.5 claim 1 , 21.9 and 26.9 degrees 2-theta±0.2 degrees 2-theta claim 1 , and also having one claim 1 , two claim 1 , three claim 1 , or four additional peaks selected from 11.3 claim 1 , 15.0 claim 1 , 21.2 claim 1 , 22.5 and 25.6 degrees 2-theta±0.2 degrees 2-theta.8. A pharmaceutical composition comprising the crystalline form according to .9. Use of the crystalline form according to in the preparation of pharmaceutical compositions and/or formulations.10. A pharmaceutical formulation comprising the crystalline form according to claim 1 , and at least one pharmaceutically acceptable excipient.11. The crystalline form according to claim 1 , for use as a medicament.12. The crystalline form according to claim 1 , for use in the treatment of Idiopathic thrombocytopenic purpura claim 1 , Thrombocytopenia and Aplastic anemia.13. A method of treating Idiopathic thrombocytopenic purpura claim 1 , Thrombocytopenia and Aplastic anemia comprising administering a therapeutically effective amount of the crystalline form according to to a subject suffering from said condition claim 1 , or otherwise in need of the treatment.